Wedbush Equities Analysts Lower Earnings Estimates for SYRE

Spyre Therapeutics, Inc. (NASDAQ:SYRE) – Analysts at Wedbush decreased their Q1 2025 earnings per share (EPS) estimates for shares of Spyre Therapeutics in a research report issued on Tuesday, November 12th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of ($0.86) per share for the quarter, down from their previous estimate of ($0.84). Wedbush has a “Outperform” rating and a $45.00 price objective on the stock. The consensus estimate for Spyre Therapeutics’ current full-year earnings is ($4.89) per share. Wedbush also issued estimates for Spyre Therapeutics’ Q2 2025 earnings at ($0.78) EPS, Q3 2025 earnings at ($0.75) EPS, Q4 2025 earnings at ($0.76) EPS, FY2025 earnings at ($3.15) EPS, FY2026 earnings at ($2.83) EPS, FY2027 earnings at ($2.82) EPS and FY2028 earnings at ($2.98) EPS.

SYRE has been the topic of a number of other research reports. Robert W. Baird increased their target price on Spyre Therapeutics from $50.00 to $65.00 and gave the company an “outperform” rating in a research report on Wednesday. Guggenheim upped their price target on Spyre Therapeutics from $50.00 to $65.00 and gave the company a “buy” rating in a research report on Friday, October 25th. Ten analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $48.57.

Spyre Therapeutics Trading Down 6.6 %

Shares of SYRE stock opened at $29.20 on Friday. The stock has a market cap of $1.50 billion, a P/E ratio of -3.91 and a beta of 2.90. The stock has a 50 day moving average of $31.34 and a 200 day moving average of $30.39. Spyre Therapeutics has a twelve month low of $8.75 and a twelve month high of $47.97.

Hedge Funds Weigh In On Spyre Therapeutics

A number of large investors have recently bought and sold shares of SYRE. Amalgamated Bank acquired a new position in shares of Spyre Therapeutics during the 2nd quarter worth $28,000. Quest Partners LLC purchased a new stake in shares of Spyre Therapeutics during the 2nd quarter worth approximately $36,000. SG Americas Securities LLC purchased a new stake in shares of Spyre Therapeutics during the 2nd quarter worth approximately $130,000. The Manufacturers Life Insurance Company grew its holdings in shares of Spyre Therapeutics by 15.0% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 43,460 shares of the company’s stock worth $1,278,000 after acquiring an additional 5,678 shares during the period. Finally, Intech Investment Management LLC purchased a new position in Spyre Therapeutics in the 3rd quarter valued at approximately $246,000. Hedge funds and other institutional investors own 80.39% of the company’s stock.

About Spyre Therapeutics

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).